We analyzed the case of a 49-year-old woman with HIV infection off-therapy with poor viro-immunological compensation,not vaccinated for SARS-COV-2,hospitalized for lobar pneumonia and severe COVID19-related respirator...We analyzed the case of a 49-year-old woman with HIV infection off-therapy with poor viro-immunological compensation,not vaccinated for SARS-COV-2,hospitalized for lobar pneumonia and severe COVID19-related respiratory failure in intensive care unit(ICU).The hospitalization was complicated by bacteraemic ventilator-associated pneumonia(VAP)caused by multidrug-resistant Acinetobacter baumannii(MDR-AB)isolated on pleural fluid culture,treated with colistin and cefiderocol for about 3 weeks.The molecular research of MDR-AB on transtracheal aspirate was negative following this therapy.The aim is to show the safety,efficacy and tolerability of colistin-based combination therapy with cefiderocol for Acinetobacter baumannii infection in HIV-infected patient.展开更多
文摘We analyzed the case of a 49-year-old woman with HIV infection off-therapy with poor viro-immunological compensation,not vaccinated for SARS-COV-2,hospitalized for lobar pneumonia and severe COVID19-related respiratory failure in intensive care unit(ICU).The hospitalization was complicated by bacteraemic ventilator-associated pneumonia(VAP)caused by multidrug-resistant Acinetobacter baumannii(MDR-AB)isolated on pleural fluid culture,treated with colistin and cefiderocol for about 3 weeks.The molecular research of MDR-AB on transtracheal aspirate was negative following this therapy.The aim is to show the safety,efficacy and tolerability of colistin-based combination therapy with cefiderocol for Acinetobacter baumannii infection in HIV-infected patient.
